Negative impact of COVID-19 pandemic on the lifestyle and management of patients with homozygous familial hypercholesterolemia
| Autor: | Sebnem Pirildar, Özlem Kuman Tunçel, Meral Kayıkçıoğlu, Levent Can, Lale Tokgozoglu |
|---|---|
| Přispěvatelé: | Ege Üniversitesi |
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty 2019-20 coronavirus outbreak Coronavirus disease 2019 (COVID-19) Endocrinology Diabetes and Metabolism Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Pharmacology toxicology MEDLINE Familial hypercholesterolemia Hyperlipoproteinemia Type II Internal medicine Pandemic Internal Medicine medicine Humans Life Style Pandemics ComputingMethodologies_COMPUTERGRAPHICS Nutrition and Dietetics SARS-CoV-2 business.industry Homozygote COVID-19 medicine.disease Editorial [No Keyword] Female Cardiology and Cardiovascular Medicine business |
| Zdroj: | Journal of Clinical Lipidology |
| ISSN: | 1933-2874 |
| DOI: | 10.1016/j.jacl.2020.09.002 |
| Popis: | [No abstract available] Sanofi Genzyme Actelion Pharmaceuticals Abbott Laboratories Pfizer Bayer Schering Amgen Fondazione Internazionale Menarini COI statement: M.K. has received honoraria (for lectures and consultancy) from Abbott, Actelion, Astra-Zeneca, Abdi Ibrahim, Aegerion, Bayer Schering, Menarini, Sanofi Genzyme, and Pfizer, and research funding from Aegerion, Amryt Pharma, Amgen, Pfizer, and Sanofi and has participated in clinical trials with Amgen, Bayer Schering, and Sanofi for the last 3 years. O.K.T. and L.H.C. had no conflicts of interest. L.T. has received honoraria/consultancy fees from Merck, Amgen, Astra, Novartis, Abbott, Daiichi Sankyo, Nova Nordisk, Pfizer, Actelion, Servier, Sanofi, Boehringer Ingelheim, Menarini, Kowa, Aegerion, and Abbott. Editorial |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect